Effectiveness of oral osmotic-methylphenidate in treatment of attention deficit hyperactivity disorder in children.
- Author:
Xue-Xia PAN
1
;
Hong-Wei MA
;
Bin WAN
;
Xiao-Mei DAI
Author Information
- Publication Type:Journal Article
- MeSH: Administration, Oral; Adolescent; Attention Deficit Disorder with Hyperactivity; drug therapy; Child; Female; Humans; Male; Methylphenidate; administration & dosage; adverse effects
- From: Chinese Journal of Contemporary Pediatrics 2008;10(4):471-474
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVEMethylphenidate is recommended as a first-line modality for treating attention deficit hyperactivity disorder (ADHD). In the past, immediate release methylphenidate (IR-MPH) was used for ADHD. Now oral osmotic-methylphenidate (OROS-MPH) is used for ADHD in China. This study was designed to investigate the efficacy and safety of OROS-MPH for treatment of ADHD in children.
METHODSNinety-nine children with ADHD were randomly administered with OROS-MPH (18 mg/time, once daily) and IR-MPH (5 mg/ time, twice or three times per day). After 6 weeks of treatment, the therapeutic effects were evaluated by the SNAP-IV and the IVA-CPT.
RESULTSFifty patients completed the 6-week treatment. The effective rate (83.3% vs 75%) and the complete remission rate (44% vs 25%) in the OROS-MPH treatment group were higher than that in the IR-MPH treatment group. There were statistically significant differences in the SNAP-IV and IVA-CPT scores before and after treatment in the two groups (P<0.01). The two groups had a similar incidence of side effects during treatment.
CONCLUSIONSOROS-MPH for the treatment of ADHD is effective and safe in children, and its once-daily administration is more convenient.
